Our study found that in 6-year-old children, co-purified DTaP vaccination achieved a 70% seroconversion rate for pertussis anti-PT antibodies, significantly increased levels of pertussis anti-PT and anti-FHA antibodies, did not reduce diphtheria or tetanus antibody levels compared with DT vaccination, and demonstrated a good safety profile. The gene discussed is F2; the disease is pertussis.